Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13301520 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL657542 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL13669613 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL13822077 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL2056541 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| Phosphoric Acid SCHEMBL3087812 | 0.94 | P2RY2 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28349923 | 0.93 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| Pyrophosphoric Acid SCHEMBL3095141 | 0.90 | P2RY2 (0.67) | P2RY2P2RY14P2RY6P2RY4 | |
| SCHEMBL14929497 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL15059789 | 0.87 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507349-A | Probiotic bacillus compositions and methods of use | 生物编辑有限责任公司 | 2023-07-28 | — | — | CN | claimed |
| US-20160312261-A1 | ENZYMATIC PRODUCTION OF CYTOSINIC NUCLEOSIDE ANALOGUES | PLASMIA BIOTECH, S.L. (ES) | 2016-10-27 | — | — | US | claimed |
| EP-2883959-A1 | Enzymatic production of cytosinic nucleoside analogues | Plasmia Biotech, S.L. (ES) | 2015-06-17 | — | — | EP | claimed |
| EP-0218701-B1 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME | THE UNIVERSITY OF WYOMING (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0218701-A4 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME. | UNIV WYOMING (US) | 1988-09-28 | — | — | EP | claimed |
| EP-0218701-A1 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME. | UNIV WYOMING (US) | 1987-04-22 | — | — | EP | claimed |
| WO-1986006253-A1 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME | THE UNIVERSITY OF WYOMING (US) | 1986-11-06 | — | — | WO | claimed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| CN-115850356-A | Deoxynucleoside analogue and preparation method thereof | 华东理工大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-106795142-B | Stereochemically enriched compositions for delivery of nucleic acids | 川斯勒佰尔公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2022-09-01 | — | — | US | disclosed |
| EP-3544617-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | Alnylam Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098328-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-0218701-A4 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME. | UNIV WYOMING (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| US-4672111-A | 5-azido-deoxyuridine compounds and method of synthesis of the same | UNIVERSITY OF WYOMING (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0218701-A1 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME. | UNIV WYOMING (US) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986006253-A1 | 5-AZIDO DEOXYURIDINE COMPOUNDS AND METHOD OF SYNTHESIS OF THE SAME | THE UNIVERSITY OF WYOMING (US) | 1986-11-06 | — | — | WO | disclosed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SRRT, SNRPE | SLC28A1 1066/4885SLC28A2 1308/4885SLC29A1 1309/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | SLC28A1 1524/4885SLC28A2 1129/4885SLC29A1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.